Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Letermovir

FDA-approved product (tablet, oral), marketed as Prevymis.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
4 of 4

Chemical structure

Chemical structure of Letermovir
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Cytomegalovirus infection
  • Infection
  • Viral disease

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Other antivirals
FDA pharmacologic class
Cytomegalovirus DNA Terminase Complex Inhibitor FDA label ↗
Anti-infective classification
Classified as another kind of anti-infective (for example an antifungal, antiviral or antiparasitic medicine).WHO ATC J05AX18

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against K. pneumoniae, MRSA, E. coli and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA58.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli46.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae49.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis64.9% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Letermovir in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Letermovir with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Letermovir for R+ Study

    NCT07706166 · start 2026-09

    Registered record
    Registry ID
    NCT07706166
    Conditions
    Kidney Transplant; Liver Transplant
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-09
    Completion
    2029-09
    Enrolment
    146

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant; Liver Transplant
    InterventionLetermovir
    PhasePhase 4
    Registry statusNot yet recruiting

  • A Randomized Controlled Trial of Prophylactic Rituximab to Reduce Clinically Significant EBV DNAemia After Allogeneic Hematopoietic Stem Cell Transplantation

    NCT07703657 · start 2026-07-09

    Registered record
    Registry ID
    NCT07703657
    Conditions
    Allogeneic Hematopoietic Stem Cell Transplantation; Epstein-Barr Virus Reactivation; Clinically Significant EBV DNAemia
    Interventions
    Rituximab (Arm A); Standard Post-Transplant Supportive Care
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Not yet recruiting
    Start
    2026-07-09
    Completion
    2027-07-09
    Enrolment
    168

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Hematopoietic Stem Cell Transplantation; Epstein-Barr Virus Reactivation; Clinically Significant EBV DNAemia
    InterventionRituximab (Arm A); Standard Post-Transplant Supportive Care
    PhaseNot applicable
    Registry statusNot yet recruiting

  • A Vaccine (CMV-MVA Triplex Vaccine) for the Enhancement of CMV-Specific Immunity and the Prevention of CMV Viremia in Patients Undergoing Haploidentical Hematopoietic Stem Cell Transplant

    NCT07020533 · start 2026-05-08

    Registered record
    Registry ID
    NCT07020533
    Conditions
    Accelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia; Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Hematopoietic and Lymphatic System Neoplasm; Hodgkin Lymphoma; Lymphoblastic Lymphoma; Myelodysplastic Syndrome; Myelofibrosis; Myeloproliferative Neoplasm; Non-Hodgkin Lymphoma
    Interventions
    Biospecimen Collection; Electronic Health Record Review; Haploidentical Hematopoietic Cell Transplantation; Letermovir; Multi-peptide CMV-Modified Vaccinia Ankara Vaccine; Myeloablative Conditioning; Pheresis; Recombinant Granulocyte Colony-Stimulating Factor
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Recruiting
    Start
    2026-05-08
    Completion
    2029-05-30
    Enrolment
    46

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAccelerated Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive; Acute Lymphoblastic Leukemia; Acute Myeloid Leukemia; Chronic Lymphocytic Leukemia +8 more
    InterventionBiospecimen Collection; Electronic Health Record Review; Haploidentical Hematopoietic Cell Transplantation; Letermovir +4 more
    PhasePhase 1
    Registry statusRecruiting

  • Letermovir vs Valganciclovir in CMV R+ Kidney Transplant

    NCT07571135 · start 2026-05

    Registered record
    Registry ID
    NCT07571135
    Conditions
    CMV Infection; CMV; CMV Viremia; CMV Disease
    Interventions
    Letermovir; Valganciclovir CMV Prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Not yet recruiting
    Start
    2026-05
    Completion
    2028-11
    Enrolment
    300

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Infection; CMV; CMV Viremia; CMV Disease
    InterventionLetermovir; Valganciclovir CMV Prophylaxis
    PhasePhase 4
    Registry statusNot yet recruiting

  • Reducing Post-Letermovir CMV Infection: Efficacy of an Immune-Reconstitution-Based Scoring System to Guide Prophylaxis Duration

    NCT07443501 · start 2026-03-14

    Registered record
    Registry ID
    NCT07443501
    Conditions
    CMV Infection
    Interventions
    Not recorded
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2026-03-14
    Completion
    2027-12-14
    Enrolment
    1,114

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Infection
    InterventionNot recorded
    PhaseNot recorded
    Registry statusNot yet recruiting

  • VIROMARKERS GA n.101194735 - CMV and TTV Biomarkers Study Protocol

    NCT07286461 · start 2025-12-15

    Registered record
    Registry ID
    NCT07286461
    Conditions
    Allogeneic Hematopoietic Stem Cell Transplantation Recipient; CMV
    Interventions
    letermovir prophylaxis
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-15
    Completion
    2027-12-30
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAllogeneic Hematopoietic Stem Cell Transplantation Recipient; CMV
    Interventionletermovir prophylaxis
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Impact of CMV-Specific Immune Reconstitution at the End of Letermovir Prophylaxis on the Development of Late Cytomegalovirus Infection in Hematopoietic Stem Cell Transplant Recipients (INMUNOEND)

    NCT06814301 · start 2025-12-01

    Registered record
    Registry ID
    NCT06814301
    Conditions
    Cytomegalovirus Cell Mediated Immunity; Stem Cell Transplantation, Hematopoietic
    Interventions
    Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV; Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
    Study type
    OBSERVATIONAL
    Phase
    Not recorded
    Registry status
    Not yet recruiting
    Start
    2025-12-01
    Completion
    2027-09
    Enrolment
    123

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Cell Mediated Immunity; Stem Cell Transplantation, Hematopoietic
    InterventionPeriodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV; Periodic immunological monitoring of CMV-specific immune reconstitution will be performed using QTF-CMV
    PhaseNot recorded
    Registry statusNot yet recruiting

  • Letermovir Prophylaxis Duration Guided by CMV-Specific T-cell Monitoring After Allo-HSCT.

    NCT07569653 · start 2025-10-30

    Registered record
    Registry ID
    NCT07569653
    Conditions
    Cytomegalovirus Infections; Cytomegalovirus Disease; Hematopoietic Stem Cell Transplantation; Graft vs Host Disease
    Interventions
    CMV-Specific T-cell Guided Letermovir Discontinuation; Standard Letermovir Prophylaxis
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-10-30
    Completion
    2027-12
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; Cytomegalovirus Disease; Hematopoietic Stem Cell Transplantation; Graft vs Host Disease
    InterventionCMV-Specific T-cell Guided Letermovir Discontinuation; Standard Letermovir Prophylaxis
    PhasePhase 4
    Registry statusRecruiting

  • Letermovir Prophylaxis in Children With EBV-Positive T/NK-Cell Lymphoproliferative Disease and Refractory/Relapsed EBV-Associated Hemophagocytic Lymphohistiocytosis

    NCT07488728 · start 2025-10-01

    Registered record
    Registry ID
    NCT07488728
    Conditions
    EBV-associated T/NK-cell Lymphoproliferative Diseases; Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis; Letermovir
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2025-10-01
    Completion
    2026-12-31
    Enrolment
    80

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEBV-associated T/NK-cell Lymphoproliferative Diseases; Refractory/Relapsed EBV-related Hemophagocytic Lymphohistiocytosis; Letermovir
    InterventionLetermovir
    PhaseNot applicable
    Registry statusRecruiting

  • Valganciclovir vs. Letermovir for CMV Prophylaxis in Heart Transplant

    NCT07079735 · start 2025-09-12

    Registered record
    Registry ID
    NCT07079735
    Conditions
    CMV Viremia; Heart Transplant Infection; Heart Transplant Failure and Rejection
    Interventions
    Letermovir; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2 / Phase 3
    Registry status
    Recruiting
    Start
    2025-09-12
    Completion
    2029-01-17
    Enrolment
    150

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCMV Viremia; Heart Transplant Infection; Heart Transplant Failure and Rejection
    InterventionLetermovir; Valganciclovir
    PhasePhase 2 / Phase 3
    Registry statusRecruiting

  • Phase II Trials of Letermovir Prophylaxis in Patients With RRMM Undergoing Elranatamab Therapy

    NCT06920251 · start 2025-09-11

    Registered record
    Registry ID
    NCT06920251
    Conditions
    Relapsed Refractory Multiple Myeloma (RRMM)
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Recruiting
    Start
    2025-09-11
    Completion
    2028-12-31
    Enrolment
    40

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRelapsed Refractory Multiple Myeloma (RRMM)
    InterventionLetermovir
    PhasePhase 2
    Registry statusRecruiting

  • Pharmacokinetics of Oral Letermovir in Adults With End-Stage Kidney Disease With or Without Haemodialysis

    NCT07101055 · start 2025-09

    Registered record
    Registry ID
    NCT07101055
    Conditions
    End-Stage Kidney Disease (ESKD)
    Interventions
    Letermovir 480 mg [PREVYMIS]
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Not yet recruiting
    Start
    2025-09
    Completion
    2027-12
    Enrolment
    20

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEnd-Stage Kidney Disease (ESKD)
    InterventionLetermovir 480 mg [PREVYMIS]
    PhasePhase 1
    Registry statusNot yet recruiting

  • Efficacy and Safety of Leymovir Versus Valganciclovir in Prevention of Cytomegalovirus Infection and Cytomegalovirus Disease in Chinese Kidney Transplant Recipients

    NCT07266467 · start 2025-05-13

    Registered record
    Registry ID
    NCT07266467
    Conditions
    Kidney Transplant
    Interventions
    Letermovir; Valganciclovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Recruiting
    Start
    2025-05-13
    Completion
    2026-11-30
    Enrolment
    290

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionKidney Transplant
    InterventionLetermovir; Valganciclovir
    PhasePhase 4
    Registry statusRecruiting

  • A Safety Assessment of Oral Letermovir in Infants With Symptomatic Congenital Cytomegalovirus

    NCT06118515 · start 2025-02-19

    Registered record
    Registry ID
    NCT06118515
    Conditions
    Congenital Cytomegalovirus Infection
    Interventions
    Letermovir
    Study type
    INTERVENTIONAL
    Phase
    Phase 1
    Registry status
    Completed
    Start
    2025-02-19
    Completion
    2026-05-04
    Enrolment
    3

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCongenital Cytomegalovirus Infection
    InterventionLetermovir
    PhasePhase 1
    Registry statusCompleted

  • Efficacy of Extended Letermovir Prophylaxis to Prevent CMV Reactivation in High-Risk Chinese Adults Undergoing Allogeneic HSCT

    NCT06812598 · start 2024-12-16

    Registered record
    Registry ID
    NCT06812598
    Conditions
    Cytomegalovirus Infections; CMV
    Interventions
    Letermovir (0-24w）; Letermovir (0-14w）
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Recruiting
    Start
    2024-12-16
    Completion
    2026-12-31
    Enrolment
    330

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionCytomegalovirus Infections; CMV
    InterventionLetermovir (0-24w）; Letermovir (0-14w）
    PhaseNot applicable
    Registry statusRecruiting